Physicochemical features and transfection properties of chitosan/poloxamer 188/poly(D,L-lactide-co-glycolide) nanoplexes

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 2359-2372

  Cosco, Donato ^a   Federico, Cinzia ^a   Maiuolo, Jessica ^a   Bulotta, Stefania ^a   Molinaro, Roberto ^a,b   Paolino, Donatella ^a   Tassone, Pierfrancesco ^a,c   Fresta, Massimo ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^c Medical Oncology   (Italy)

Author keywords

Chitosan; Gene delivery; Nanoplexes; Poloxamer 188; Poly(D,L lactide co glycolide)

Indexed keywords

CHITOSAN; NANOSPHERE; POLOXAMER; POLYGLACTIN; DNA; EMULSION; LACTIC ACID; NANOCAPSULE; NANOCOMPOSITE; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ARTICLE; CHEMICAL COMPOSITION; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; NANOPRECIPITATION; NONVIRAL GENE DELIVERY SYSTEM; PARTICLE SIZE; PHOTOCORRELATION SPECTROSCOPY; PHYSICAL CHEMISTRY; POLYDISPERSITY INDEX; PRECIPITATION; SURFACE PROPERTY; ZETA POTENTIAL; CHEMISTRY; EMULSION; GENETICS; HELA CELL LINE; PROCEDURES; SYNTHESIS; ULTRASTRUCTURE;

CHITOSAN; DNA; EMULSIONS; HELA CELLS; HUMANS; LACTIC ACID; NANOCAPSULES; NANOCOMPOSITES; POLOXAMER; POLYGLYCOLIC ACID; TRANSFECTION;

EID: 84900840865     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S58362     Document Type: Article

References (45)

1. Brannon-Peppas L, Ghosn B, Roy K, Cornetta K. Encapsulation of nucleic acids and opportunities for cancer treatment. Pharm Res. 2007;24(4):618-627.
2. Nayerossadat N, Maedeh T, Ali PA. Viral and nonviral delivery systems for gene delivery. Adv Biomed Res. 2012;1:27.
3. Midoux P, Breuzard G, Gomez JP, Pichon C. Polymer-based gene delivery: a current review on the uptake and intracellular trafficking of polyplexes. Curr Gene Ther. 2008;8(5):335-352.
4. Tarahovsky YS. Cell transfection by DNA-lipid complexes-lipoplexes. Biochemistry. 2009;74(12):1293-1304.
5. Tros de Ilarduya C, Sun Y, Düzgüneş N. Gene delivery by lipoplexes and polyplexes. Eur J Pharm Sci. 2010;40(3):159-170.
6. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cell and tissue. Adv Drug Deliv Rev. 2003;55(3):329-347.
7. Paolino D, Cosco D, Celano M, et al. Gemcitabine-loaded biocompatible nanocapsules for the effective treatment of human cancer. Nanomedicine (Lond). 2013;8(2):193-201.
8. Sahoo SK, Panyam J, Prabha S, Labhasetwar V. Residual polyvinyl alcohol associated with poly(D, L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J Control Release. 2002;82(1):105-114.
9. Cosco D, Molinaro R, Morittu VM, Cilurzo F, Costa N, Fresta M. Anticancer activity of 9-cis-retinoic acid encapsulated in PEG-coated PLGA-nanoparticles. J Drug Deliv Sci Technol. 2011;21(5):395-400.
10. Mahapatro A, Singh DK. Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines. J Nanobiotechnology. 2011;9:55.
11. Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Préat V. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release. 2012;161(2):505-522.
12. Celia C, Cosco D, Paolino D, Fresta M. Nanoparticulate devices for brain drug delivery. Med Res Rev. 2010;31(5):716-756.
13. Paolino D, Cosco D, Molinaro R, Celia C, Fresta M. Supramolecular devices to improve the treatment of brain diseases. Drug Discov Today. 2011;16(7-8):311-324.
14. Zakeri-Milani P, Loveymi BD, Jelvehgari M, Valizadeh H. The characteristics and improved intestinal permeability of vancomycin PLGA-nanoparticles as colloidal drug delivery system. Colloids Surf B Biointerfaces. 2013;103:174-181.
15. Keijzer C, Slütter B, van der Zee R, Jiskoot W, van Eden W, Broere F. PLGA, PLGA-TMC and TMC-TPP nanoparticles differentially modulate the outcome of nasal vaccination by inducing tolerance or enhancing humoral immunity. PLoS One. 2011;6(11):e26684.
16. Giannavola C, Bucolo C, Maltese A, et al. Influence of preparation conditions on acyclovir-loaded poly-D, L-lactic acid nanospheres and effect of PEG-coating on ocular drug bioavailability. Pharm Res. 2003;20(4):584-590.
17. Patil Y, Panyam J. Polymeric nanoparticles for siRNA delivery and gene silencing. Int J Pharm. 2009;367(1-2):195-203.
18. Yuan X, Shah BA, Kotadia NK, Li J, Gu H, Wu Z. The development and mechanism studies of cationic chitosan-modified biodegradable PLGA nanoparticles for efficient siRNA drug delivery. Pharm Res. 2010;27(7):1285-1295.
19. Ventura CA, Cannavà C, Stancanelli R, et al. Gemcitabine-loaded chitosan microspheres. Characterization and biological in vitro evaluation. Biomed Microdevices. 2011;13(5):799-807.
20. Saranya N, Moorthi A, Saravanan S, Pandima Devi M, Selvamurugan N. Chitosan and its derivatives for gene delivery. Int J Biol Macromol. 2011;48(2):234-238.
21. Guan XP, Quan DP, Liao KR, Tao Wang, Peng Xiang, Mai KC. Preparation and characterization of cationic chitosan-modified poly(D, L-lactide-co-glycolide) copolymer nanospheres as DNA carriers. J Biomater Appl. 2008;22(4):353-371.
22. Niu X, Zou W, Liu C, Zhang N, Fu C. Modified nanoprecipitation method to fabricate DNA-loaded PLGA nanoparticles. Drug Dev Ind Pharm. 2009;35(11):1375-1383.
23. Nafee N, Taetz S, Schneider M, Schaefer UF, Lehr CM. Chitosan-coated PLGA nanoparticles for DNA/RNA delivery: effect of the formulation parameters on complexation and transfection of antisense oligonucleotides. Nanomedicine. 2007;3(3):173-183.
24. Tahara K, Yamamoto H, Hirashima N, Kawashima Y. Chitosan-modified poly(D, L-lactide-co-glycolide) nanospheres for improving siRNA delivery and gene-silencing effects. Eur J Pharm Biopharm. 2010;74(3):421-426.
25. Tahara K, Yamamoto H, Kawashima Y. Cellular uptake mechanisms and intracellular distributions of polysorbate 80-modified poly(D, L-lactide-co-glycolide) nanospheres for gene delivery. Eur J Pharm Biopharm. 2010;75(2):218-224.
26. Vasir JK, Labhasetwar V. Biodegradable nanoparticles for cytosolic delivery of therapeutics. Adv Drug Deliv Rev. 2007;59(8):718-728.
27. Sato T, Ishii T, Okahata Y. In vitro gene delivery mediated by chitosan. Effect of pH, serum, and molecular mass of chitosan on the transfection efficiency. Biomaterials. 2001;22(15):2075-2080.
28. Mao S, Sun W, Kissel T. Chitosan-based formulations for delivery of DNA and siRNA. Adv Drug Deliv Rev. 2010;62(1):12-27.
29. Amoozgar Z, Park J, Lin Q, Yeo Y. Low molecular-weight chitosan as a pH-sensitive stealth coating for tumor-specific drug delivery. Mol Pharm. 2012;9(5):1262-1270.
30. Moloughney JG, Weisleder N. Poloxamer 188 (p188) as a membrane resealing reagent in biomedical applications. Recent Pat Biotechnol. 2012;6(3):200-211.
31. Paolino D, Celia C, Trapasso E, Cilurzo F, Fresta M. Paclitaxel-loaded ethosomes®: potential treatment of squamous cell carcinoma, a malignant transformation of actinic keratoses. Eur J Pharm Biopharm. 2012;81(1):102-112.
32. Cosco D, Rocco F, Ceruti M, Vono M, Fresta M, Paolino D. Self-assembled squalenoyl-cytarabine nanostructures as a potent nanomedicine for treatment of leukemic diseases. Int J Nanomedicine. 2012;7:2535-2546.
33. Cosco D, Bulotta A, Ventura M, et al. In vivo activity of gemcitabine-loaded PEGylated small unilamellar liposomes against pancreatic cancer. Cancer Chemother Pharmacol. 2009;64(5):1009-1020.
34. Paolino D, Cosco D, Cilurzo F, et al. Improved in vitro and in vivo collagen biosynthesis by asiaticoside-loaded ultradeformable vesicles. J Control Release. 2012;162(1):143-151.
35. Yan F, Zhang C, Zheng Y, et al. The effect of poloxamer 188 on nanoparticle morphology, size, cancer cell uptake, and cytotoxicity. Nanomedicine. 2010;6(1):170-178.
36. Zeng P, Xu Y, Zeng C, Ren H, Peng M. Chitosan-modified poly(D, L-lactide-co-glycolide) nanospheres for plasmid DNA delivery and HBV gene-silencing. Int J Pharm. 2011;415(1-2):259-266.
37. Iannone M, Cosco D, Cilurzo F, et al. A novel animal model to evaluate the ability of a drug delivery system to promote the passage through the BBB. Neurosci Lett. 2010;469(1):93-96.
38. Liang GF, Zhu YL, Sun B, et al. PLGA-based gene delivering nanoparticle enhance suppression effect of miRNA in HePG2 cells. Nanoscale Res Lett. 2011;6:447.
39. Haedicke A, Blume A. Interactions of Pluronic block copolymers with lipid monolayers studied by epi-fluorescence microscopy and by adsorption experiments. J Colloid Interface Sci. 2013;407:327-338.
40. Amodio N, Di Martino MT, Foresta U, et al. miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1. Cell Death Dis. 2012;3:e436.
41. Di Martino MT, Leone E, Amodio N, et al. Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. Clin Cancer Res. 2012;18(22):6260-6270.
42. Rossi M, Pitari MR, Amodio N, et al. miR-29b negatively regulates human osteoclastic cell differentiation and function: implications for the treatment of multiple myeloma-related bone disease. J Cell Physiol. 2013;228(7):1506-1515.
43. Licciardi M, Paolino D, Celia C, Giammona G, Cavallaro G, Fresta M. Folate-targeted supramolecular vesicular aggregates based on polyaspartyl-hydrazide copolymers for the selective delivery of antitumoral drugs. Biomaterials. 2010;31(28):7340-7354.
44. Wang H, Zhao P, Su W, et al. PLGA/polymeric liposome for targeted drug and gene co-delivery. Biomaterials. 2010;31(33):8741-8748.
45. Cosco D, Paolino D, Cilurzo F, Casale F, Fresta M. Gemcitabine and tamoxifen-loaded liposomes as multidrug carriers for the treatment of breast cancer diseases. Int J Pharm. 2012;422(1-2):229-237.